Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramlintide on Top of Semaglutide in Obese People With Prediabetes
NCT06619015Phase 3Withdrawn
- Sponsor
- Esbjerg Hospital - University Hospital of Southern Denmark
- Start
- Apr 2025
- Primary completion
- Apr 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of pramlintide in obesity, prediabetes, sponsored by Esbjerg Hospital - University Hospital of Southern Denmark. Planned start Apr 2025; status: withdrawn.
02
Drugs
pramlintide
03
Conditions
obesityprediabetes
Beyond the preview
Go deeper on NCT06619015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619015.